




REPUBLIC OF THE PHILIPPINES
DEPARTMENT OF FINANCE
BUREAU OF INTERNAL REVENUE



14 March 2022

REVENUE MEMORANDUM CIRCULAR NO. 58-2022

SUBJECT : Publishing the Full Text of the March 10, 2022 Letter from the Food and Drug Administration (FDA) of the Department of Health (DOH) Endorsing Updates to the List of VAT-Exempt Medicines Under Republic Act (R.A.) No. 11534 Known as the Corporate Recovery and Tax Incentives for Enterprises (CREATE) Act


TO : All Internal Revenue Officers and Others Concerned

For the information and guidance of all internal revenue officers, employees and others concerned, attached is the March 10, 2022 letter (Annex "A") from Dr. Oscar G. Gutierrez, Jr., OIC-Director General of the FDA, for the correction of the names of certain medicines for hypertension and COVID-19 treatment as previously published in the List of VAT-Exempt Medicines Under R.A. No. 11534 or the CREATE Act.

All concerned are hereby enjoined to be guided accordingly and give this Circular as wide a publicity as possible.

CAESAR R. DULAY
Commissioner of Internal Revenue

By:


MARISSA O. CABREROS
Deputy Commissioner
Legal Group
Officer-in-Charge

0318